Futibatinib in Combination With (Chemo)Immunotherapy in Colorectal Cancer and Other Solid Tumor Entities
Status:
NOT_YET_RECRUITING
Trial end date:
2027-09-01
Target enrollment:
Participant gender:
Summary
The FUTURE trial is a prospective, multicentre, exploratory, open-label phase II platform trial. Its goal is to evaluate the efficacy, feasibility and safety of futibatinib combined with immunotherapeutic, targeted or chemotherapeutic agents in colorectal and other solid tumors and to additionally identify biomarkers that correlate with clinical outcome.
Phase:
PHASE2
Details
Lead Sponsor:
Institut fr Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Collaborator:
Universittsmedizin Mainz, I. Medizinische Klinik, Forschungslabor Prof. Mhler